Empagliflozin reduces the risk of diabetic patients cardiovascular death by 38%

A scientific seminar on 'Novel glucose lowering medication — Empagliflozin, a groundbreaking innovation for Type 2 Diabetes" was held in Dhaka recently, says a press release.

Endocrinologist Assistant Professor Dr Tanjina Hossain presented that the use of novel Empagliflozin (Empa) for type-2 diabetes also reduces the risk of cardiovascular death by 38%.

The American Diabetes Association (ADA) 2019 guidelines recommended the benefits of Empagliflozin for type 2 diabetes patients who have cardiovascular disease, heart failure, kidney disease and obesity.

Japan Bangladesh joint venture pharmaceutical company NIPRO JMI Pharma Ltd. arranged a scientific seminar.

CEO of NIPRO JMI Pharma Ltd. Md. Mizanur Rahman, Eminent Endocrinologists Prof. Dr. Zafar Ahamed Latif, Prof. Dr. Md. Faruque Pathan, Prof. Dr. S. M. Ashrafuzzaman, Prof. Emeritus Dr. Hajera Mahtab, Dr. Tanjina Hossain were present in the Scientific Seminar among others.